Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated September 04, 2021, titled "Dr. Reddy s Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox).".
Press Release Sep 04 2021
Filed with NSE · · 2 pages · English
Watch Dr. Reddy's Laboratories' latest callDr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings Call · Replay · Oct 23Read the transcript of Dr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings CallRelease
Dr. Reddy's Laboratories Ltd. on 6ix
Earlier from Dr. Reddy's Laboratories
- Press Release Sep 02 2021
- Press Release Aug 31 2021
- Press Release Aug 04 2021
- Press Release Aug 03 2021
- Press Release Jul 27 2021
Later from Dr. Reddy's Laboratories
- Press Release Sep 07 2021
- Press Release Oct 07 2021
- Press Release Oct 14 2021
- Press Release Oct 15 2021
- Press Release Oct 19 2021
Follow Dr. Reddy's Laboratories into a list and get an email when it puts out news.
Follow Dr. Reddy's Laboratories